<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072705</url>
  </required_header>
  <id_info>
    <org_study_id>3-2019-0195</org_study_id>
    <nct_id>NCT04072705</nct_id>
  </id_info>
  <brief_title>Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke</brief_title>
  <official_title>A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SAMJIN PHARM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that &quot;the poor metabolizer or intermediate metabolizer of the
      cytochrome P450 2C19 genotype in patients with acute ischemic stroke is associated with
      increased risk of composite cardiovascular events (recurrent stroke, myocardial infarction,
      cardiovascular death) compared to those who of extensive metabolizer of the cytochrome P450
      2C19 genotype&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel, one of the antiplatelet agents used for secondary prevention in patients with
      ischemic stroke and coronary artery disease, has been shown to have a superior antiplatelet
      effect compared to aspirin, and is therefore being administered to many patients with stroke
      and coronary artery disease. Clopidogrel inhibits platelet-derived ADP receptor, P2Y12, in
      the liver to produce an anti-platelet effect. It has been suggested that clopidogrel
      resistance could be occurred from drug-drug interaction via the same pharmacological
      metabolic pathway. Previous studies reported that the genotypes of Cytochrome P450 2C19,
      which is involved in the metabolism of clopidogrel in the liver, lead to differences in drug
      response and recurrence rates of cardiovascular disease. The risk of recurrence of ischemic
      stroke was reported to be about 4 times higher in patients with a poor metabolizer or
      intermediate metabolizer genotype of the Cytochrome P450 2C19 genotype compared to the
      extensive metabolizer genotype. This genotypes of Cytochrome P450 2C19 were also different
      according to race.

      The researches about cytochrome P450 2C19 genotype and clopidogrel resistance have been
      conducted mainly in patients with coronary artery disease and are not known in stroke
      patients. Few studies have examined whether the resistance of clopidogrel according to the
      genotype of cytochrome P450 2C19 in stroke patients is related to the occurrence and/or
      recurrence of cardiovascular disease. The hypothesis of this study is that &quot;the poor
      metabolizer or intermediate metabolizer of the cytochrome P450 2C19 genotype in patients with
      acute ischemic stroke is associated with increased risk of cardiovascular disease and
      mortality compared to those who of extensive metabolizer of the cytochrome P450 2C19
      genotype&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>composite cardiovascular events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Occurrence of composite cardiovascular events (recurrent stroke, myocardial infarction, cardiovascular death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Occurrence of ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Occurrence of transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Revascularization of cerebral, coronary, peripheral artery or aorta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Occurrence of myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early neurological worsening</measure>
    <time_frame>up to 7 days</time_frame>
    <description>increased National Institutes of Health Stroke Scale within 7 day after admission)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis</measure>
    <time_frame>3 months</time_frame>
    <description>ratio of modified Rankin scale (0 - 2) at 3 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of major adverse events</measure>
    <time_frame>Tile frame: participants will be followed at 0, 1, 3, 6 months</time_frame>
    <description>Occurrence of major bleeding (fatal bleeding, symptomatic cerebral hemorrhage, ocular hemorrhage, bleeding which needs absolute bed rest or hospitalization or transfusion (more than 2 pack of whole blood or RBC).
Occurrence of all-causes mortality</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2927</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>1. Poor and intermediate metabolizer group</arm_group_label>
    <description>Poor and intermediate metabolizer group: acute ischemic stroke patients with poor and intermediate metabolizer genotype of cytochrome P450 2C19 for clopidogrel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Extensive metabolizer group</arm_group_label>
    <description>Extensive metabolizer group: acute ischemic stroke patients with Extensive metabolizer genotype of cytochrome P450 2C19 for clopidogrel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>General principles of care and judgement of researcher</intervention_name>
    <description>Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.</description>
    <arm_group_label>1. Poor and intermediate metabolizer group</arm_group_label>
    <arm_group_label>2. Extensive metabolizer group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cytochrome P450 2C19 genotype
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute ischemic stroke who received clopidogrel 75 mg to 300 mg (in the case
        of loading dose) within 24 hours of symptom onset and who underwent Cytochrome P450 2C19
        genotyping test
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ischemic stroke confirmed by brain CT or MRI

          2. Patient who received clopidogrel within 72 hours after onset of ischemic stroke

          3. Adults over 19 years

          4. Patients who agreed to participate in this study within 7 days after ischemic stroke

          5. Patients who underwent Cytochrome P450 2C19 genotype test.

        Exclusion Criteria:

          1. Patients who currently take anticoagulation or is expected to take anticoagulation
             with 6 months from the screening date

          2. Patients who need other antiplatelet drugs except aspirin and clopidogrel

          3. Patients who were taking clopidogrel prior to ischemic stroke

          4. Patients scheduled for coronary artery stenting, coronary artery bypass surgery,
             carotid endarterectomy, carotid and cerebral artery stenting

          5. Patients with severe comorbidities or active cancer with an estimated life expectancy
             of less than two years

          6. Patients who participated in other drug clinical trials within the past 30 days

          7. Patients with high risk source of potential cardiac source of embolism in TOAST
             classification

          8. Patients who are expected to unable to participate or continue the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KyungYul Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KyungYul Lee</last_name>
    <phone>82-2-2019-4632</phone>
    <phone_ext>3325</phone_ext>
    <email>kylee@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Man Jung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae-Sung Lim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eung-Gyu Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Kwan Cha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49267</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bong-Goo Yoo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Changwon Fatima Hospital</name>
      <address>
        <city>Changwon</city>
        <zip>51394</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Hee Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Hallym University Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <zip>24253</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chul Ho Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Kangwon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <zip>24289</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong Heon Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Il Sohn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang-Ha Hwang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Daejeon Eulji Medical Center Eulji University</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do-Hyung Kim, DH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Gimpo Woori Hospital</name>
      <address>
        <city>Gimpo-si</city>
        <zip>10099</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Chul Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology National Health Insurance Service Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>10444</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Hong Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Myongji Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>10475</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Ho Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61453</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong Hwan Ahn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man-Seok Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Hallym University Dongtan Sacred Heart Hospital</name>
      <address>
        <city>Hwaseong-si</city>
        <zip>18450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Min Uk Jang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Wonkwang University Hospital</name>
      <address>
        <city>Iksan</city>
        <zip>54538</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Young Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Hoon Shin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee-Kwon Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Catholic Kwandong University International St.Mary`s Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sagn Joon An, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beom Joon Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Inje University Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>01757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Won Han, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>02053</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tai Hwan Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology KyungHee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Hyuk Heo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sungwook Yu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Hwa Jung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Severance Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Dae Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology National Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>04564</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Yoon Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyun Young Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology KyungHee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Chul Shin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yerim Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Gangnam Severance Hospital, Yonsei Univ. College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-Yul Lee, MD, PhD</last_name>
      <phone>82-2-2019-3325</phone>
      <email>kylee@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Kyung-Yul Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yo Han Jung, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwang-Yeol Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Ewha Womans University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07804</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Jin Song, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Kyung Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Yonsei University Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seo Hyun Kim, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004 Mar 23;109(11):1335-8. Epub 2004 Mar 15.</citation>
    <PMID>15023882</PMID>
  </reference>
  <reference>
    <citation>Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003 Jan 7;107(1):32-7.</citation>
    <PMID>12515739</PMID>
  </reference>
  <reference>
    <citation>Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005 Apr 19;45(8):1157-64. Review.</citation>
    <PMID>15837243</PMID>
  </reference>
  <reference>
    <citation>Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22.</citation>
    <PMID>19106084</PMID>
  </reference>
  <reference>
    <citation>Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363-75. doi: 10.1056/NEJMoa0808227. Epub 2008 Dec 22.</citation>
    <PMID>19106083</PMID>
  </reference>
  <reference>
    <citation>Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009 Jan 24;373(9660):309-17. doi: 10.1016/S0140-6736(08)61845-0. Epub 2008 Dec 26.</citation>
    <PMID>19108880</PMID>
  </reference>
  <reference>
    <citation>Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.</citation>
    <PMID>19706858</PMID>
  </reference>
  <reference>
    <citation>Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, Li X, Huang L, Johnston SC, Zhao X, Liu L, Zhang Q, Wang G, Wang Y, Wang Y. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. Circulation. 2017 Jan 3;135(1):21-33. doi: 10.1161/CIRCULATIONAHA.116.024913. Epub 2016 Nov 2. Review.</citation>
    <PMID>27806998</PMID>
  </reference>
  <reference>
    <citation>Han SW, Kim YJ, Ahn SH, Seo WK, Yu S, Oh SH, Nam HS, Choi HY, Yoon SS, Kim SH, Lee JY, Lee JH, Hwang YH, Lee KO, Jung YH, Lee J, Sohn SI, Kim YN, Lee KA, Bushnell CD, Lee KY. Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping. J Stroke. 2017 Sep;19(3):356-364. doi: 10.5853/jos.2017.01249. Epub 2017 Sep 29.</citation>
    <PMID>29037010</PMID>
  </reference>
  <reference>
    <citation>Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS, Kim EY, Shin JG. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit. 2007 Aug;29(4):455-9.</citation>
    <PMID>17667801</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, Wang Y; CHANCE investigators. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA. 2016 Jul 5;316(1):70-8. doi: 10.1001/jama.2016.8662.</citation>
    <PMID>27348249</PMID>
  </reference>
  <reference>
    <citation>CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39.</citation>
    <PMID>8918275</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 25, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Kyung-Yul Lee</investigator_full_name>
    <investigator_title>KyungYul Lee, Professor</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Cytochrome P450 2C19</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

